Corcept Therapeutics Incorporated (CORT - Free Report) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
The open-label study is evaluating if the addition of Korlym increases the effect of Halaven in patients with TNBC whose tumors express the glucocorticoid receptor (GR), one of the receptors to which Korlym binds. The trial enrolled 21 patients with GR-positive tumors and two with tumors whose GR status is currently unknown. Out of these patients, 3 patients exhibited a partial response, defined as a 30% or greater reduction in tumor size, 8 had stable disease and 11 had progressive disease.
Preliminary data from the trial showed that the combination is active in treating TNBC. Final results are expected in mid 2016.
We note that Korlym is already approved for the once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. A potential label expansion of the drug will boost its sales.
Concurrently, Corcept provided updates on other candidates in its pipeline. The company has begun dosing patients in a phase 1/II trial on CORT125134, in combination with Abraxane, for the treatment of a range of solid-tumor cancers. While the first phase will identify a recommended dose of Abraxane and CORT125134, the second phase will test the combination's efficacy against a range of tumor types in one or more 20-patient cohorts. Initial results are expected in 2017.
Meanwhile, the University of Chicago is conducting a phase II trial on Korlym, in combination with Xtandi, for the treatment of metastatic, castration-resistant prostate cancer. The institution also plans to conduct a phase II trial on Korlym, in combination with Abraxane, for the treatment of patients with TNBC. The trial will be conducted in collaboration with Corcept and Celgene Corp. .
Corcept currently holds a Zacks Rank # 3 (Hold). A couple of better-ranked stocks in the healthcare sector are Pfizer Inc. (PFE - Free Report) and Bristol-Myers Squibb Co. (BMY - Free Report) , both sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Corcept Therapeutics Incorporated (CORT - Free Report) released preliminary efficacy data from a phase I/II study on Korlym for the treatment of treat triple-negative breast cancer (TNBC).
The open-label study is evaluating if the addition of Korlym increases the effect of Halaven in patients with TNBC whose tumors express the glucocorticoid receptor (GR), one of the receptors to which Korlym binds. The trial enrolled 21 patients with GR-positive tumors and two with tumors whose GR status is currently unknown. Out of these patients, 3 patients exhibited a partial response, defined as a 30% or greater reduction in tumor size, 8 had stable disease and 11 had progressive disease.
Preliminary data from the trial showed that the combination is active in treating TNBC. Final results are expected in mid 2016.
We note that Korlym is already approved for the once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. A potential label expansion of the drug will boost its sales.
Concurrently, Corcept provided updates on other candidates in its pipeline. The company has begun dosing patients in a phase 1/II trial on CORT125134, in combination with Abraxane, for the treatment of a range of solid-tumor cancers. While the first phase will identify a recommended dose of Abraxane and CORT125134, the second phase will test the combination's efficacy against a range of tumor types in one or more 20-patient cohorts. Initial results are expected in 2017.
Meanwhile, the University of Chicago is conducting a phase II trial on Korlym, in combination with Xtandi, for the treatment of metastatic, castration-resistant prostate cancer. The institution also plans to conduct a phase II trial on Korlym, in combination with Abraxane, for the treatment of patients with TNBC. The trial will be conducted in collaboration with Corcept and Celgene Corp. .
Corcept currently holds a Zacks Rank # 3 (Hold). A couple of better-ranked stocks in the healthcare sector are Pfizer Inc. (PFE - Free Report) and Bristol-Myers Squibb Co. (BMY - Free Report) , both sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE
Get the latest research report on PFE - FREE
Get the latest research report on CORT - FREE